-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Sd9EvrLVqC6J7Q+l/8GSsIS1TKgfxRIZjTDwUYguSIJa6AbNvWwkt2nneJp9tLzB CIzHHXt0/WA9u/k33vPgZg== 0001127602-08-004244.txt : 20080613 0001127602-08-004244.hdr.sgml : 20080613 20080613143234 ACCESSION NUMBER: 0001127602-08-004244 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080611 FILED AS OF DATE: 20080613 DATE AS OF CHANGE: 20080613 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WHITE JOHN P CENTRAL INDEX KEY: 0001238970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 08898020 MAIL ADDRESS: STREET 1: OSI PHARMACEUTICALS INC STREET 2: 58 S SERVICE RD STE 110 CITY: MELVILLE STATE: NY ZIP: 11747 4 1 form4.xml PRIMARY DOCUMENT X0202 4 2008-06-11 0000729922 OSI PHARMACEUTICALS INC OSIP 0001238970 WHITE JOHN P C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE NY 11747 1 Common Stock 2008-06-11 4 A 0 2500 0 A 23323 D Stock Option (Right to Buy) 38.63 2008-06-11 4 A 0 7500 0 A 2009-06-11 2015-06-10 Common Stock 7500 7500 D Represents the formula grant of Restricted Stock to the director upon re-election to the Board of Directors of OSI Pharmaceuticals, Inc. 25% of the Restricted Stock will vest one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. 25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. /s/ Michael G. Atieh, attorney-in-fact for Mr. White 2008-06-13 -----END PRIVACY-ENHANCED MESSAGE-----